ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

These stocks offer impressive long-term upside with downside protection.

AbbVie ABBV stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks ...

AbbVie ABBV generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

Trial data suggest a JAK inhibitor beats the leading biologic ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...